Urology News and Research

Latest Urology News and Research

Endo International’s revenues increase $800 million to 37% in fourth quarter 2014

Endo International plc today reported fourth quarter 2014 revenues of $800 million, an increase of 37 percent compared to fourth quarter 2013 revenues of $585 million, including new product revenue from 2014 strategic M&A transactions.

2 Mar 2015

Taiho announces submission of TAS-102 MAA to EMA for treatment of mCRC

Taiho Pharma Europe Ltd., a subsidiary of Japan based Taiho Pharmaceutical Co., Ltd., announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug intended for use in the treatment of refractory metastatic colorectal cancer (mCRC).

2 Mar 2015

Study reports 10% reduction in overall C-section births in Portugal

A new study reports a significant decline in the rate of cesarean section (C-section) births in Portugal. Findings published in Acta Obstetricia et Gynecologica Scandinavica, a journal of the Nordic Federation of Societies of Obstetrics and Gynecology, indicate a 10% reduction in overall C-section rates between 2009 and 2014, with a 14% reduction in state-hospitals during the same time period.

2 Mar 2015

Patients who receive chemotherapy after bladder cancer surgery demonstrate 30% lower risk of death

Patients that received chemotherapy after bladder cancer surgery demonstrated an approximately 30% lower risk of death than those that underwent surgery alone, according to an analysis to be presented by researchers at the Icahn School of Medicine at Mount Sinai at the 2015 Genitourinary Cancers Symposium.

28 Feb 2015

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years.

27 Feb 2015

Simple urine test could guide clinicians to better treat bladder cancer patients

Researchers at the University of Birmingham believe that a simple urine test could help to guide clinicians in the treatment of bladder cancer patients.

26 Feb 2015

Frailty assessment test can accurately predict complications after major operation

Frailty has been used to predict how well a patient may recover from a major operation. Because frailty assessments are not routinely utilized in busy surgical practices, surgeons at Emory University School of Medicine in Atlanta have discovered that a short, approximately one-minute assessment can accurately determine how likely a patient is to have complications after an operation.

26 Feb 2015

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis.

25 Feb 2015

Actavis files ANDA to market Budesonide Extended-release Tablets

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Budesonide Extended-release Tablets, 9 mg.

25 Feb 2015

Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced the New Drug Application (NDA) for TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), has been accepted for review by the U.S. Food and Drug Administration.

23 Feb 2015

Actavis obtains final approval from FDA for generic Subutex

Actavis plc today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Reckitt Benckiser's Subutex (Buprenorphine 2 mg and 8 mg sublingual tablets).

21 Feb 2015

Research findings lay groundwork for improving treatment assessment for men with prostate cancer

UCLA researchers have found that radiation therapy is the most common treatment for men with prostate cancer regardless of the aggressiveness of the tumor, risk to the patient and overall patient prognosis. These findings lay the groundwork for improved treatment assessment by physicians and to better inform men fighting the disease.

20 Feb 2015

New research finds that synthetic flame retardants can cause metabolic and liver problems

Chemicals used as synthetic flame retardants that are found in common household items such as couches, carpet padding, and electronics have been found to cause metabolic and liver problems that can lead to insulin resistance, which is a major cause of obesity, according to new research from the University of New Hampshire.

20 Feb 2015

Nicotine metabolite supports learning, memory by amplifying action of primary chemical messenger

Nicotine's primary metabolite supports learning and memory by amplifying the action of a primary chemical messenger involved in both, researchers report.

19 Feb 2015

Leaf Healthcare's wireless patient monitoring system can improve pressure ulcer prevention processes

Clinicians from the Veterans Affairs Medical Center in Boise, Idaho, will demonstrate that Leaf Healthcare's new, wireless patient monitoring system can significantly improve a caregiver's pressure ulcer prevention processes. Their presentation will take place at the National Pressure Ulcer Advisory Panel Biennial Conference in Orlando, Fla., this week.

19 Feb 2015

Findings may help doctors recommend appropriate treatments, improve patient outcomes

Like a car's front and back bumpers, your cell's chromosomes are capped by "telomeres" that protect this genetic material against deterioration. Still, after enough replications, a chromosome's telomeres break down and once they reach a certain point of degradation, the cell dies. This is one reason that cells are mortal: telomeres only last so long. That is, unless the enzyme telomerase builds new material onto the worn telomeres to reinforce these chromosomal "bumpers". Telomere repair can be a good thing, but in some cases it's not: overactive telomerase can lengthen telomeres until a cell becomes immortal…leading to cancer.

18 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

Urology News and Research

Latest Urology News and Research

Endo International’s revenues increase $800 million to 37% in fourth quarter 2014

Taiho announces submission of TAS-102 MAA to EMA for treatment of mCRC

Study reports 10% reduction in overall C-section births in Portugal

Patients who receive chemotherapy after bladder cancer surgery demonstrate 30% lower risk of death

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Simple urine test could guide clinicians to better treat bladder cancer patients

Frailty assessment test can accurately predict complications after major operation

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

Actavis files ANDA to market Budesonide Extended-release Tablets

Taiho Oncology announces acceptance of TAS-102 NDA for review by FDA

Actavis obtains final approval from FDA for generic Subutex

Research findings lay groundwork for improving treatment assessment for men with prostate cancer

New research finds that synthetic flame retardants can cause metabolic and liver problems

Nicotine metabolite supports learning, memory by amplifying action of primary chemical messenger

Leaf Healthcare's wireless patient monitoring system can improve pressure ulcer prevention processes

Findings may help doctors recommend appropriate treatments, improve patient outcomes

Actavis provides overview of standalone global pharmaceutical development pipeline

Cabazitaxel therapy may be more effective in treating prostate cancer

UBMD physician discusses the dangers of hypothermia

Tissue and cell diagnostics market reaches $7.7 billion in 2014

Mastering RNA extraction for plant and fungal research – eBook eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Urology News and Research

Latest Urology News and Research

Mastering RNA extraction for plant and fungal research – eBook eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in